Susquehanna International Group
SCPS

Susquehanna International Group’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Susquehanna International Group’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,723
Closed -$14K – 14431
2022
Q1 		$14K Buy
+20,723
New +$20K ﹤0.01% 12708
2021
Q2 		– Sell
-14,799
Closed -$125K – 13536
2021
Q1 		$125K Buy
+14,799
New +$155K ﹤0.01% 11754

Other funds holding SCPS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MRCM
M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group's SCPS Position: Q2 2022 in Review

Susquehanna International Group sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q2 2022, closing a stake of 20,723 shares — an estimated $14K sold.

Susquehanna International Group first reported a position in SCPS in Q1 2021 and held it in 2 quarters. The position peaked at $125K in Q1 2021. 17 funds tracked by Wall St. Rank hold SCPS as of Q2 2022.

  • Susquehanna International Group reported no remaining Scopus BioPharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Susquehanna International Group sold 20,723 Scopus BioPharma Inc. Common Stock shares in Q2 2022, an estimated $14K.
  • Susquehanna International Group first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Susquehanna International Group's Scopus BioPharma Inc. Common Stock position peaked at $125K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q2 2022.

Based on Susquehanna International Group's 13F filing for Q2 2022, filed 15 Aug 2022.